LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Allakos Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On December 18, 2019, Seligman Research published a report alleging that the Company, among other issues, “buried the results for the two AK001 studies it conducted,” has “a checkered history of conducting small, low-credibility trials, marked by . . . discrepancies, omissions, cherry-picking, and other red flags,” and engaged in “[f]lagrant nepotism in key clinical roles.”
On this news, the Company’s stock price fell $13.25, or nearly 10%, to close at $119.28 per share on December 18, 2019, thereby injuring investors.
If you purchased Allakos securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles H. Linehan, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.